DE69124382D1 - Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände - Google Patents

Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände

Info

Publication number
DE69124382D1
DE69124382D1 DE69124382T DE69124382T DE69124382D1 DE 69124382 D1 DE69124382 D1 DE 69124382D1 DE 69124382 T DE69124382 T DE 69124382T DE 69124382 T DE69124382 T DE 69124382T DE 69124382 D1 DE69124382 D1 DE 69124382D1
Authority
DE
Germany
Prior art keywords
nutrient
containing product
pct
hypocaloric
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69124382T
Other languages
English (en)
Other versions
DE69124382T3 (de
DE69124382T2 (de
Inventor
Linda Fryklund
Peter Gluckman
Anna Skottner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69124382(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of DE69124382D1 publication Critical patent/DE69124382D1/de
Application granted granted Critical
Publication of DE69124382T2 publication Critical patent/DE69124382T2/de
Publication of DE69124382T3 publication Critical patent/DE69124382T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69124382T 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände Expired - Fee Related DE69124382T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor
PCT/SE1991/000557 WO1992003154A1 (en) 1990-08-24 1991-08-22 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients

Publications (3)

Publication Number Publication Date
DE69124382D1 true DE69124382D1 (de) 1997-03-06
DE69124382T2 DE69124382T2 (de) 1997-06-26
DE69124382T3 DE69124382T3 (de) 2003-09-11

Family

ID=20380208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124382T Expired - Fee Related DE69124382T3 (de) 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände

Country Status (14)

Country Link
US (1) US6034059A (de)
EP (1) EP0546007B2 (de)
JP (1) JP2521867B2 (de)
AT (1) ATE147988T1 (de)
AU (1) AU650050B2 (de)
CA (1) CA2088674A1 (de)
DE (1) DE69124382T3 (de)
DK (1) DK0546007T3 (de)
ES (1) ES2097816T5 (de)
GR (1) GR3022935T3 (de)
IE (1) IE912615A1 (de)
PT (1) PT98764B (de)
SE (1) SE9002731D0 (de)
WO (1) WO1992003154A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
ATE495443T1 (de) * 2000-11-28 2011-01-15 Premacure Ab Reduzierung des risikos für komplikationen bei frühgeburten
JP3896879B2 (ja) * 2002-03-22 2007-03-22 日本電気株式会社 トラヒック監視システム
WO2006130769A2 (en) * 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
CA1320441C (en) * 1986-01-09 1993-07-20 Douglas W. Wilmore Use of growth hormone for nitrogen retention under hypocaloric conditions
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
DE3852636T2 (de) * 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).

Also Published As

Publication number Publication date
JPH05509323A (ja) 1993-12-22
EP0546007A1 (de) 1993-06-16
PT98764B (pt) 1999-01-29
CA2088674A1 (en) 1992-02-25
EP0546007B2 (de) 2003-01-29
DE69124382T3 (de) 2003-09-11
ATE147988T1 (de) 1997-02-15
ES2097816T3 (es) 1997-04-16
US6034059A (en) 2000-03-07
WO1992003154A1 (en) 1992-03-05
GR3022935T3 (en) 1997-06-30
IE912615A1 (en) 1992-02-26
AU8448891A (en) 1992-03-17
DK0546007T3 (da) 1997-03-17
EP0546007B1 (de) 1997-01-22
JP2521867B2 (ja) 1996-08-07
ES2097816T5 (es) 2003-07-16
SE9002731D0 (sv) 1990-08-24
PT98764A (pt) 1993-09-30
DE69124382T2 (de) 1997-06-26
AU650050B2 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69731540D1 (de) Behandlung von diarrhoe
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE198830T1 (de) Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
ATE64300T1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
ATE243521T1 (de) Verwendung von biopolymeren zur behandlung der muskeln
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
UA40974A (uk) Спосіб лікування міопії у дітей та підлітків

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN AB, STOCKHOLM, SE

8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP., EMERYVILLE, CALIF., US

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee